Incyte (INCY) EBIT Growth (1y) (2011 - 2026)
Incyte (INCY) EBIT Growth (1y) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 8.32% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 19.82% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 145.20% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 269.85% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 76.24% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -36.55% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1,528.74% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 99.51% |
| 10 | Incyte | 24.15 Bn | 19.61 Bn | 1.57 Bn | 31.60% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 31.60% |
| Mar 31, 2026 | 46.77% |
| Dec 31, 2025 | 11.39% |
| Sep 30, 2025 | 203.60% |
| Jun 30, 2025 | 210.91% |
| Mar 31, 2025 | 123.26% |
| Dec 31, 2024 | 61.00% |
| Sep 30, 2024 | -31.96% |
| Jun 30, 2024 | -346.74% |
| Mar 31, 2024 | 271.01% |
| Dec 31, 2023 | 167.17% |
| Sep 30, 2023 | 55.16% |
| Jun 30, 2023 | -23.84% |
| Mar 31, 2023 | -78.75% |
| Dec 31, 2022 | -36.70% |
| Sep 30, 2022 | -41.22% |
| Jun 30, 2022 | 80.66% |
| Mar 31, 2022 | 17.96% |
| Dec 31, 2021 | -32.57% |
| Sep 30, 2021 | 4,320.02% |